Virginia Commonwealth University
Richmond, Virginia, 23298, United States
NCT Number: NCT03514953
The proposed research will examine the role of physical activity (PA) on altering sleep quality (SQ) while systematically examining novel mechanisms that may drive changes in SQ. Specifically, the study will examine how a 2 week reduction in PA alters sleep quality in young, healthy individuals. Additionally, during this reduction in PA, the study will examine changes in inflammation, oxidative stress, and sympathetic activity to identify potential mechanisms for alterations in sleep quality.
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Not applicable
Richmond, Virginia, 23298, United States
Sleep, which makes up approximately one third of an individual's life, plays a vital role in normal bodily functioning by regulating metabolic and endocrine function. Disturbed sleep, defined as any alteration to normal sleep patterns, is highly prevalent, affecting 35% and 41% of the general population in the United States and has been linked to poor cardiovascular health, diabetes, obesity, dyslipidemia, and hypertension. Young adults are a population at high risk for disturbed sleep-related health outcomes due to negative lifestyle behaviors such as alcohol consumption, drug use, study patterns, and excessive screen time that remain with advancing age. Due to the importance of improving or maintaining health outcomes through adequate sleep quality (SQ), the proposed research will examine the role of physical activity (PA) on altering SQ while systematically examining novel mechanisms that may drive changes in SQ. Specifically, this study will examine how alterations (increases and decreases) in PA impact SQ and how these alterations modify inflammation, oxidative stress, and sympathetic stimulation in young adults.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.
Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.
Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns.
Time frame: Day 7 to Day 21
Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))
Time frame: Day 21 to Day 28
Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of inflammation with greater levels indicating more inflammation
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of inflammation with greater levels indicating more inflammation
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of inflammation with greater levels indicating more inflammation
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of catecholamine production with greater levels indicating more production
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of catecholamine production with greater levels indicating more production
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of oxidative stress with greater levels indicating more oxidative stress
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of oxidative stress with greater levels indicating more oxidative stress
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of popliteal artery dilation after 5 minutes of lower limb occlusion
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of brachial artery dilation after 5 minutes of lower limb occlusion
Time frame: Measured on Day 7, Day 14, Day 21, Day 28
Measurement of leg blood flow during 1 minute of passive leg movement
Virginia Commonwealth University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04702724
Consolidation, Sleep
Chicago, Illinois, United States
View Trial DetailsNCT05378373
Psychiatric Health, Sleep
Durham, North Carolina, United States
View Trial DetailsNCT05138848
Alzheimer Disease, Alzheimer Disease, Late Onset
Pittsburgh, Pennsylvania, United States
View Trial Details